The Combined Use of Disease Activity and Infliximab Serum Trough Concentrations for Early Prediction of (Non-)Response to Infliximab in Rheumatoid Arthritis
British Journal of Clinical Pharmacology - United Kingdom
doi 10.1111/bcp.12142
Full Text
Open PDFAbstract
Available in full text
Categories
Date
November 20, 2013
Authors
Publisher
Wiley